Source: Eur Respir J, 51 (6) 1800376; 10.1183/13993003.00376-2018
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Tanja Tran, Samy Suissa. The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies. Eur Respir J, 51 (6) 1800376; 10.1183/13993003.00376-2018

Member's Comments

No comment yet.

Related content which might interest you: The clinical efficacy of pulmonary hypertension-specific agents in idiopathic pulmonary fibrosis: A systematic review and meta-analysis Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study Source: Eur Respir J, 53 (3) 1801587; 10.1183/13993003.01587-2018 Year: 2019 Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review Source: Eur Respir Rev, 29 (157) 190158; 10.1183/16000617.0158-2019 Year: 2020 A systematic review and individual participant data meta-analysis of MMP-7 and outcomes in idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Exploring barriers to Pirfenidone adherence in patients with idiopathic pulmonary fibrosis: a prospective study Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 STARMAP: an observational study to assess disease-relevant outcomes using home-monitoring devices in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Concomitant corticosteroid with anti-fibrotic therapy for idiopathic pulmonary fibrosis: a prospective multicenter study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study Source: Eur Respir Rev 2008; 17: 116-122 Year: 2008 Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review Source: Eur Respir J 2015; 46: 1113-1130 Year: 2015 Multi-institutional prospective cohort study of prognostic factors in patients with idiopathic pulmonary fibrosis receiving long-term oxygen therapy. Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Safety and benefits of beta-blockers in chronic obstructive pulmonary disease: a review of current evidence and meta-analysis Source: International Congress 2018 – Cardiovascular morbidities in COPD Year: 2018 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns Source: Eur Respir J 2016; 48: 1523-1524 Year: 2016 Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns Source: Eur Respir J 2016; 48: 1524-1526 Year: 2016 Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis Source: Eur Respir Rev 2012; 21: 147-151 Year: 2012 The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis Source: International Congress 2019 – Clinical and translational studies of bronchiectasis and non-TB mycobacterial infection Year: 2019 Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019 How are recovery and recurrence of COPD exacerbations defined in observational studies? A systematic review Source: International Congress 2018 – Epidemiology of COPD : from exarcebations and comorbidities to asthma-COPD overlap syndrome (ACOS) Year: 2018 Methodological issues in therapeutic trials of COPD Source: Eur Respir J 2008; 31: 927-933 Year: 2008